G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Trial watch: dietary interventions for cancer therapy.
Sarah Levesque,Jonathan Pol,Gladys Ferrere,Lorenzo Galluzzi,Laurence Zitvogel,Laurence Zitvogel,Guido Kroemer +6 more
TL;DR: The scientific rationale for harnessing dietary interventions to improve the efficacy of anticancer therapy is discussed and up-to-date information on clinical trials currently investigating this possibility is presented.
Journal ArticleDOI
Apoptosis and karyogamy in syncytia induced by the HIV-1-envelope glycoprotein complex.
TL;DR: In a model culture system of syncytium-dependent cell death, HeLa cells stably transfected with a lymphotropic HIV-1 Env gene (HeLa Env) were fused by co-culture with CD4/CXCR4-expressing He La cells (Hela CD4), indicating that apoptosis induced by exogenous stimuli obeys other principles than spontaneoussyncytial apoptosis.
Journal ArticleDOI
Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy
TL;DR: Recent data on 1,798 mammary carcinoma specimens indicate that patients harboring neoplastic cells that lack immunohistochemical signs of autophagy or that have lost HMGB1 expression have indeed a poor prognosis.
Journal ArticleDOI
Strategies for the etiological therapy of cystic fibrosis.
TL;DR: A global strategy for CF research and development based on a reconciliatory approach is proposed and the utility of preclinical biomarkers that may guide the personalized, patient-specific implementation of CF therapies are discussed.
Journal ArticleDOI
Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer.
Gautier Stoll,Kristina Iribarren,Judith Michels,Alexandra Leary,Laurence Zitvogel,Isabelle Cremer,Guido Kroemer +6 more
TL;DR: The contention that, at least in some cancers, loss of CALR expression may negatively affect immunosurveillance, thereby reducing patient survival is supported.